Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 8:00 am ET. The event can be accessed via a webcast on Theravance.com in the Investors section. A replay will be available for 30 days post-event. Theravance Biopharma is committed to delivering Medicines that Make a Difference and is known for its FDA-approved YUPELRI^® inhalation solution for COPD. The company focuses on addressing significant unmet patient needs through its innovative pipeline.

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 8:00 am ET (5:00 am PT/1:00 pm GMT).

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301742892.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma participating in the SVB Securities Global Biopharma Conference?

Theravance Biopharma will participate in the conference on February 15, 2023, at 8:00 am ET.

How can I access the webcast of Theravance Biopharma's Fireside Chat?

The webcast can be accessed on Theravance.com under the Investors section.

What is the significance of Theravance Biopharma's participation in the conference?

It highlights their commitment to innovation and sharing insights into their biopharmaceutical developments.

What is YUPELRI and its indication?

YUPELRI is an FDA-approved inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

How long will the replay of the Fireside Chat be available?

The replay will be archived on Theravance's website for 30 days.